Principal Financial Group Inc. acquired a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 16,878 shares of the company’s stock, valued at approximately $166,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Amalgamated Bank purchased a new stake in Neumora Therapeutics in the 4th quarter valued at about $29,000. New York State Common Retirement Fund purchased a new stake in Neumora Therapeutics in the 4th quarter valued at about $118,000. SG Americas Securities LLC purchased a new stake in Neumora Therapeutics in the 2nd quarter valued at about $566,000. Nan Fung Group Holdings Ltd purchased a new stake in Neumora Therapeutics in the 1st quarter valued at about $871,000. Finally, Auour Investments LLC purchased a new stake in Neumora Therapeutics in the 1st quarter valued at about $1,445,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.
Neumora Therapeutics Stock Performance
NMRA stock opened at $12.03 on Monday. The company’s 50 day moving average price is $11.59 and its 200 day moving average price is $11.55. Neumora Therapeutics, Inc. has a fifty-two week low of $8.33 and a fifty-two week high of $21.00.
Analyst Ratings Changes
A number of analysts have issued reports on NMRA shares. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research note on Thursday. Mizuho started coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $29.00 price target on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.11.
Read Our Latest Analysis on NMRA
Insider Buying and Selling
In related news, CFO Joshua Pinto sold 31,642 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the transaction, the chief financial officer now directly owns 154,658 shares of the company’s stock, valued at $1,821,871.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 26.40% of the company’s stock.
Neumora Therapeutics Profile
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Further Reading
- Five stocks we like better than Neumora Therapeutics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How to Use the MarketBeat Stock Screener
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Election Stocks: How Elections Affect the Stock Market
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Want to see what other hedge funds are holding NMRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report).
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.